Friberg L E, Brindley C J, Karlsson M O, Devlin A J
Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden.
Eur J Clin Pharmacol. 2000 Nov;56(8):567-74. doi: 10.1007/s002280000181.
DMDC (2'-deoxy-2'-methylidenecytidine) is-a potential antitumour deoxycytidine analogue of cytosine arabinoside. The major dose-limiting toxicity of DMDC is haematological depression, particularly neutropenia, and therefore quantitative exposure-toxicity relationships for DMDC are warranted.
Data on the survival fraction at nadir of leukocytes, neutrophils and platelets from 66 patients receiving a once-daily regimen and 85 patients receiving a twice-daily regimen of DMDC were related to DMDC concentration-time profiles using area under the plasma concentration-time curve (AUC), threshold and general models. A semiphysiological model of neutrophils versus time after DMDC administration included transient compartments to imitate the differentiation stages in the bone marrow.
The relationship between plasma DMDC concentration-time profiles and the haematological toxicity at nadir was best described using an AUC-dependent model with separate functions for once- and twice-daily dosing, indicating schedule dependence of DMDC effects, even if differences in treatment duration had a similar explanatory value. Twice-daily dosing was associated with greater toxic effects than once-daily dosing. The AUC required for a 70% reduction in the neutrophils was 16 mg.h/l and 4.2 mg.h/l for the once- and twice-daily regimens, respectively. The semiphysiological model included nine proliferating transient compartments that were sensitive to DMDC in a schedule-dependent manner, five non-mitotic, non-sensitive compartments and one compartment for circulating neutrophils.
The haematological toxicity of DMDC is schedule dependent. The survival fractions of leukocytes, neutrophils and platelets are predicted to be lower when given on a twice-daily regimen than on a once-daily regimen. A semiphysiological model with transient compartments successfully described the entire time course of neutropenia after DMDC administration.
DMDC(2'-脱氧-2'-亚甲基胞苷)是一种潜在的抗肿瘤脱氧胞苷类似物,结构与阿糖胞苷相似。DMDC的主要剂量限制性毒性是血液学抑制,尤其是中性粒细胞减少,因此有必要确定DMDC的定量暴露-毒性关系。
采用血浆浓度-时间曲线下面积(AUC)、阈值和通用模型,将66例接受每日一次DMDC治疗方案患者以及85例接受每日两次DMDC治疗方案患者的白细胞、中性粒细胞和血小板最低点存活分数数据与DMDC浓度-时间曲线相关联。DMDC给药后中性粒细胞随时间变化的半生理模型包括模拟骨髓中分化阶段的瞬时区室。
血浆DMDC浓度-时间曲线与最低点血液学毒性之间的关系,使用AUC依赖性模型能得到最佳描述,该模型对每日一次和每日两次给药有不同函数,表明DMDC效应具有给药方案依赖性,即使治疗持续时间差异具有相似的解释价值。每日两次给药比每日一次给药的毒性作用更大。每日一次和每日两次给药方案使中性粒细胞减少70%所需的AUC分别为16mg·h/l和4.2mg·h/l。半生理模型包括9个对DMDC敏感的增殖瞬时区室、5个非有丝分裂、不敏感区室和1个循环中性粒细胞区室。
DMDC的血液学毒性具有给药方案依赖性。预计每日两次给药方案下白细胞、中性粒细胞和血小板的存活分数低于每日一次给药方案。带有瞬时区室的半生理模型成功描述了DMDC给药后中性粒细胞减少的整个时间过程。